Clinical trials evaluating angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the setting of acute myocardial infarction

By Salam Amar M  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 3, 2003-03 ,pp. : 501-507

Informa Healthcare

Access to resources Recommend Favorite

Long-Term Treatment with Angiotensin-Converting Enzyme Inhibitors, Beta-Blockers or a Combination of Angiotensin-Converting Enzyme Inhibitors and Beta-Blockers in Low-Risk Patients after Acute Myocardial Infarction: The ABC Study

By  

Heart Drug, Vol. 1, Iss. 1, 2001-03 ,pp. : 20-25

Karger

Access to resources Recommend Favorite

Under-Utilisation of -Blockers After Acute Myocardial Infarction: Pharmacoeconomic Implications

By Bradford W.D.  

PharmacoEconomics, Vol. 15, Iss. 3, 1999-03 ,pp. : 257-268

Adis International

Access to resources Recommend Favorite

Effects of Angiotensin Receptor Blockade on Haemodynamics and Gene Expression after Myocardial Infarction

By Gurevich A.K.  

Drugs in R&D, Vol. 3, Iss. 4, 2002-01 ,pp. : 239-249

Adis International

Access to resources Recommend Favorite

Drug interactions with angiotensin receptor blockers

By Böhler Steffen   Pittrow David   Bramlage Peter   Kirch Wilhelm  

Expert Opinion on Drug Safety, Vol. 4, Iss. 1, 2005-01 ,pp. : 7-18

Informa Healthcare

Access to resources Recommend Favorite